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Abstract: Chronic heart failure often leads to worsening of the renal function. Mediators of this process include
inflammatory and neuroendocrine factors. CCN1 (Cyr 61), a member of growth factor-inducible immediate
early genes, which modulates inflammation and fibrogenesis, is excreted with urine in the early phase of acute
renal injury and may be involved in the pathogenesis of the cardiorenal syndrome. The aim of the study was to
evaluate CCN1 protein abundance and localization in the kidney of IL-6-deficient C57BL/6J (IL-6 KO) mice
and respective wild-type (WT) animals in basal conditions and in animals with chronic heart failure twelve
weeks after myocardial infarction. Age- and sex-matched mice from both strains subjected to sham operation
served as controls. One group of WT animals subjected to myocardial infarction was treated with antagonist of
AT1 receptor telmisartan over 12 weeks. Abundance and localization of CCN1 protein in kidney were assessed
with Western blotting and immunohistochemistry, respectively. In all groups the strongest immunohistochemi-
cal reaction for CCN1 was observed in distal convoluted tubules and in smaller arteries, however, the total
expression of CCN1 protein was lower in IL-6 KO mice in comparison to WT animals. The main difference in
CCN1 distribution between the examined genotypes was lack of reaction in internal renal medulla and very
weak reaction in proximal convoluted tubules in IL-6 KO mice. Experimental heart failure only slightly attenu-
ated the expression of CCN1 protein in the kidney of WT mice and had no effect in IL-6 KO mice. Although,
blockade of AT1 receptor did not alter CCN1 protein expression in kidneys of WT mice after myocardial infarc-
tion, it significantly changed its CCN1 distribution in the renal tubular system. (Folia Histochemica et Cytobiolo-
gica 2013, Vol. 51, No. 1, 84–91)
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Introduction
The kidney controls the volume of blood that is re-
quired for proper perfusion of organs. Primary dys-
function of either the kidney or the heart may initiate
impairment of the other, which has been described
as the cardiorenal syndrome [1]. Acute worsening of
cardiac performance leading to deterioration of re-
nal function is classified as type 1, and chronic heart
failure causing progressive kidney dysfunction as type
2 of the cardiorenal syndrome [1]. Interactions be-
tween the heart and the kidney seem to be multidi-
rectional and involve hemodynamic, neurohormonal
and inflammatory factors. Myocardial infarction was
shown to worsen kidney function in clinical as well as
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in experimental conditions [2, 3]. Glomerular filtra-
tion rate declines early following myocardial infarc-
tion and persists as a chronic abnormality and is ac-
companied by initial transient macrophage infiltra-
tion and progressive fibrosis of the renal interstitium.
Upregulation of proinflammatory interleukin 6 (IL-6)
after myocardial infarction [3, 4], in addition to the
induction of other proinflammatory cytokines, com-
promises cardiac performance, and is postulated to
be one of early predictive factors for secondary acute
kidney injury [5]. In chronic heart failure (CHF), lev-
el of IL-6 is elevated proportionally to the severity of
circulatory insufficiency [6], and is an independent
predictor of mortality [7]. Increased plasma IL-6 con-
centration was also described in chronic kidney dis-
ease [8]. After acute myocardial infarction the level
of IL-6 in plasma of patients with previous renal dys-
function is more increased than in those with well
preserved kidney function [9]. This underlies the im-
portance of this cytokine and inflammatory mecha-
nisms in general in the pathogenesis of chronic car-
diorenal syndrome. IL-6 evokes cellular responses via
its membrane receptor and the two main downstream
pathways: JAK2/STAT3 and MAPK/ERK [10] and
activation of JAK2/STAT3 was previously reported
to induce CCN1 expression [11]. CCN1 (also known
as Cyr 61 — cysteine rich protein 61) belongs to the
CCN family (the acronym derived from first letters
of the three members first discovered: Cyr61, CTGF
(connective tissue growth factor), and NOV (neph-
roblastoma overexpressed) that comprises six secret-
ed proteins grouped together on the basis of a similar
modular secondary structure [12]. CCN1 is a multi-
functional matricellular protein, that plays essential
roles in cardiovascular development, wound healing,
fibrogenesis and regulation of inflammatory process
[13]. Muramatsu et al. showed that experimental re-
nal ischemia in rats and mice induces upregulation of
CCN1, mainly in the proximal straight tubules, and
its elevated urine level was postulated to be a marker
of renal ischemia/reperfusion injury [14]. The present
knowledge about the regulation and the role of CCN1
in healthy and diseased kidneys is very scant. In ro-
dent kidney the basal expression of CCN1 protein is
rather low [14]. In rat kidney it was observed in the
outer stripe of outer medulla and in some afferent
and efferent arterioles, while experimental anti-Thy-
1 glomerulonephritis induced CCN1 expression in
podocytes [15]. In different tissues the expression of
CCN1 can be regulated by over 30 factors [16]. In the
heart and in the vasculature, angiotensin II was shown
to induce significantly CCN1 expression via its recep-
tor type 1 (AT1R) [17, 18]. AT1R is expressed in all
renal tubular and vascular segments and in mesan-
gial cells [19, 20]. It regulates tubular reabsorption
and blood pressure, and seems to contribute to the
development of renal dysfunction in cardiorenal syn-
drome [19, 21]. It remains unknown whether AT1R
mediates renal expression of CCN1and if there are
alterations of renal CCN1 expression in chronic re-
nal dysfunction related to chronic circulatory failure,
which corresponds to the cardiorenal syndrome type
2. The aim of this study was to evaluate CCN1 pro-
tein expression and localization in mouse kidney in
basal conditions and in the model of chronic heart
failure and to check whether IL-6 deficiency and AT1
receptor blockade affects renal CCN1 expression.
Material and methods
Animals. Male 14-16 week-old IL-6 gene knockout C57BL/
/6J IL-6-/-TMKopf (IL-6 KO) and wild-type (WT) reference
strain C57BL/6J mice were obtained from the Center for
Experimental Medicine of the Medical University of Bia-
lystok. Both strains were originally purchased from the Jack-
son Laboratories (West Grove, PA, USA). Animals were
kept at constant temperature of 22oC ± 1oC in 12:12 dark-
light cycle with constant access to chow and water.
Myocardial infarction. Sixty four animals were subjected
to coronary artery ligation to produce myocardial infarc-
tion. Twenty sex- and age-matched animals from both used
strains subjected to sham operation were used as controls.
The operation was performed as described previously with
some modifications [22]. Briefly, animals were anaesthetized
with isoflurane. After intubation of the trachea mice were
put on a heated operating pad and ventilated with oxygen-
enriched air using rodent respirator (Minivent, Harvard
Apparatus, USA). The chest was opened by left-sided inci-
sion in the fifth intercostal space, followed by opening of
the pericardial sac and exposure of the anterior wall of the
heart. In sham operated animals after 10 further minutes
the chest was closed in layers with reposition of muscles. In
order to induce myocardial ischemia in the remaining ani-
mals, the left coronary artery was ligated just proximally to
its main bifurcation using Prolene 7.0 suture with atraumatic
needle. Efficacy of myocardial ischemia was assessed visual-
ly as pale discoloration of the cardiac anterior wall. After
closing of the chest wall, animals were further ventilated with
oxygen-rich air without anaesthetic until spontaneous breath
was evident (usually about 2 minutes). Mice were transferred
to cages kept at 27°C and left for one hour to recover. Nine-
teen WT animals subjected to coronary artery ligation were
for the next twelve weeks treated with telmisartan (#T8949,
Sigma, St. Louis, MO, USA) at a dose 1 mg/kg/day in drink-
ing water [17] and constituted the MI-Telmisartan group,
while the remaining mice after myocardial infarction (MI
group) or sham operated (Sham) were not subjected to fur-
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ther treatment. All mice were sacrificed by cervical disloca-
tion. Their hearts were excised and taken for further exami-
nations, then the right kidney was fixed in isotonic PBS-buff-
ered formalin and the left kidney was snap frozen in liquid
nitrogen and stored at –80oC until further analyses.
Myocardial dysfunction was diagnosed based on echocar-
diography performed eight weeks after surgery with the use of
the M12L (14 mHz) ultrasound transducer. In addition gene
expression of atrial natriuretic peptide (ANP) in the samples
of the left ventricle myocardium was established using the two-
step real time PCR method with the TaqMan Gene Expres-
sion Assay (Applied Biosystems, USA). Mice that did not show
a visible area of akinesis in echocardiography and decrease of
left ventricle ejection fraction below 35%, or that did not
present at least 2-fold increase of ANP gene expression in com-
parison to control group were excluded from the analyses. Forty
three animals from three infarction groups (29 WT mice, of
which 11 were treated with telmisartan and 14 IL-KO mice)
and twenty sham-operated (10 WT and 10 IL-6 KO) mice were
included in the final analysis.
Genotyping. Genomic DNA for IL-6 genotyping was isolated
from mouse tails using “Genomic mini” kit (A&A Biotech-
nology, Poland) according to the enclosed protocol. PCR was
performed using PCR Master Mix (2x) (Fermentas, Lithua-
nia) and custom made primers (F 5’-CCATCCAGTTGCCT-
TCTTG-3’, R 5’-AAGTGCATCATCGTTGTTCATAC-3’).
After initial denaturation at 94oC over 5 minutes, amplifica-
tion was performed in thirty PCR cycles under the following
conditions: 94oC 20 seconds, 52oC 30 seconds, 72oC 3 min.,
with final extension at 72oC for 10 minutes. Then, DNA was
separated by electrophoresis on 1% agarose gel with ethidium
bromide. GeneRuler DNA Ladder Mix (Fermentas, Lithua-
nia) was used for PCR product size identification.
Western blotting. Western blotting procedure was per-
formed as described previously [23]. Protein extracts were
subjected to SDS-PAGE and blotted onto nitrocellulose
membranes (BioRad, USA). Equal loading was confirmed
using Ponceau Red staining (Sigma, USA). Primary anti-
bodies recognizing mouse CCN1 were bought from Santa
Cruz Biotechnology (#sc-13100, Santa Cruz Biotechnolo-
gy, Santa Cruz, CA, USA). Secondary antibodies were con-
jugated with horseradish peroxidase (Star54, Serotec, Ox-
ford, UK). Blots were visualized using enhanced chemilu-
minescence reaction (Pierce, Rockford, IL, USA), and ex-
posed on x-ray film (X-Omat Blue, Kodak, Rochester, NY).
Results were scanned and quantified using Scion Image
software (Scion Corporation, Frederick, MD, USA). The
results of particular experiments were related to the expres-
sion of proteins in the control group, which was set as 100%.
Immunohistochemical evaluation of CCN1 protein local-
ization. Formalin-fixed, paraffin-embedded tissue blocks
were sectioned into 5 µm slices. After deparafinization and
rehydration, sections were pretreated with proteinase K
solution and then blocked with 10% donkey serum in phos-
phate buffered saline (PBS) for 1 hour at room tempera-
ture. The endogenous peroxidase activity was blocked with
3% H2O2. The primary antibodies against CCN1 (H-78, #sc-
13100, SantaCruz Biotechnology, SantaCruz, CA, USA)
were applied at 1:100 dilution in PBS for 90 minutes at room
temperature. Then slides were incubated with proper sec-
ondary antibody (Star54, Serotec, Oxford, UK) conjugated
with horseradish peroxidase at dilution 1:100 for one hour
at room temperature. In the next step sections were rinsed
with PBS and incubated with the DAB substrate (DAB Per-
oxidase Substrate Kit, Vector Laboratories, Burlingame,
CA, USA) for 10 minutes. Nuclei were counterstained with
hematoxylin. Negative control of staining was performed in
the corresponding sections by omitting the primary antibody.
Ethical issues. The experimental procedures were carried
out according to the European Council Directive of 24 No-
vember 1986 (6/609/EEC) and were approved by the Local
Ethics Committee of Bialystok.
Statistics. Results were presented as mean ± standard de-
viation (SD). U Mann-Whitney test was used for statistical




Material from wild-type animals yielded DNA frag-
ments of the size ca. 1476 bp, whereas the respective
DNA fragments from IL-6 KO animals included
a fragment of neomycin cassette and were of the size
ca. 2400 bp (Figure 1).
Western blot analysis
Western blotting analysis using an antibody against
CCN1 revealed higher abundance of CCN1 protein
Figure 1. IL-6 genotyping of wild-type and IL-6 deficient
animals. DNA electrophoresis on agarose gel. Lanes from
left: 1 to 3 — wild-type (C57BL/6J) animals; 4 — DNA
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in the kidney of WT sham-operated animals than in
IL-6 deficient sham-operated mice (Figure 2), how-
ever this difference did not reach the level of statisti-
cal significance. Twelve weeks after myocardial inf-
arction a slight decrease of CCN1 protein in the kid-
ney of both WT and IL-6 KO mice was observed. Post-
operative treatment of WT mice with an antagonist
of AT1 receptor, telmisartan, did not change the lev-
el of CCN1 in kidney extracts.
Immunohistochemical evaluation of CCN1
In normal kidney from WT sham-operated mice
CCN1 protein was expressed in both renal cortex and
medulla. In the cortex, the strongest expression was
observed in distal convoluted tubules and to a lesser
degree in proximal convoluted tubules, especially in
the brush border of tubular epithelium (Figure 3A).
In the medulla, a similar intensity of CCN1 reaction
as in proximal convoluted tubules was seen in the
outer stripe of outer medulla, which corresponds to
proximal straight tubules, and in the thick portion of
Henle’s loop, as well as in the epithelium of collect-
ing ducts. A strong CCN1-positive reaction was ob-
served in smaller arteries (Figure 3B), however, not
in large arteries. Moreover, CCN1-positive reaction
was visible in some cells of glomeruli, probably
podocytes ( Figure 3B).
Twelve weeks after myocardial infarction attenu-
ation of CCN1-positive reaction throughout the re-
nal cortex in both proximal and distal convoluted tu-
bules, as well as in small arteries and glomeruli was
observed (Figure 3C). In the outer stripe of outer
medulla the intensity of reaction was not changed as
compared to WT sham operated animals. Lower
CCN1-positive staining in small arteries was noted in
both sham operated and infracted IL-6 KO groups
(Figure 3H).
In the group of animals subjected to myocardial
infarction and treated with telmisartan, the charac-
teristic distribution of CCN1 protein was observed in
the kidney cortex. The intensity of CCN1-positive
staining in straight proximal tubules was comparable
to the WT infarcted group. CCN1 protein was almost
absent in proximal convoluted tubules and in the in-
ner medulla (Figure 3E and 3F), while strong CCN1-
positive staining was observed in distal convoluted
tubules (Figure 3D). In the outer stripe of outer me-
dulla the intensity of reaction was comparable to that
of other groups of WT animals. Similarly to the WT
infarcted group, less intensive CCN1-positive stain-
ing was observed in smaller arteries, with no reaction
in large arteries, as compared with WT sham mice.
Moreover, slight attenuation of CCN1-positive stain-
ing was observed in glomeruli.
In IL-6 deficient mice the intensity of CCN1-pos-
itive reaction and distribution of CCN1 protein in
sham-operated animals (Figure 3G) and after myo-
cardial infarction (Figure 3H) did not differ. There
were, however, some differences in CCN1 distribu-
tion as compared with WT animals: CCN1 was down-
regulated in proximal convoluted tubules and in tu-
bules of the internal part of renal medulla. The in-
tensity of CCN1-positive reaction in distal convolut-
ed tubules was similar to WT animals. Also,
differences in CCN1 staining between smaller and
larger arteries were observed as described in the oth-
er groups of mice. Similarly to WT animals, a slight
attenuation of CCN1 immunoreactivity in the glom-
eruli was observed in mice after infarction (Figure
3G and 3H).
Discussion
Results of the present study indicate that CCN1 pro-





















Figure 2. Relative abundance of CCN1 protein measured
by Western blot. The measurements were performed on
kidney samples obtained from sham-operated mice (Sham)
and mice who underwent myocardial infarction 12 weeks
earlier (MI), IL-6 deficient (IL-6 KO) or wild type (WT)
mice, as well as from ‘infarcted’ mice treated with antago-
nist of AT1 receptor, telmisartan (Tel); (A) representative
Western blot of CCN1 and beta-actin (reference);
(B) columns on the graph represent mean values ± SEM
obtained from 10–16 animals
CCN1
b-actin
WT Sham WT MI m WT MITel IL6KO Sham IL6KO MI
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Figure 3. Immunohistochemical analyses of CCN1 protein expression in kidney from sham-operated and myocardial
infarcted mice of IL-6 deficient (IL-6 KO) or wild type (WT) genotype. In sham-operated WT mice kidney the strongest
reaction for CCN1 was seen in distal convoluted tubules (A) and smaller arteries (B), while weaker reaction was present
in proximal convoluted tubules (A and B). CCN1 protein was also present in some podocytes (B). In the kidney from
infarcted WT mice the reaction for CCN1 protein was weaker, however, its distribution was similar as in the sham-
operated ones (C). In kidney cortex from WT infarcted animals treated with telmisartan, a strong reaction for CCN1
protein was present in distal convoluted tubules, and there was no reaction in proximal convoluted tubules (D), while in
the medulla positive CCN1 reaction was present in the outer stripe of outer medulla — arrowheads (E and F — higher
magnification). Immunohistochemical reaction for CCN1 in IL-6 KO sham-operated (G) and IL-6 KO infarcted mice (H)
was comparable and was weaker than in WT sham-operated and infarcted animals. Magnifications: A, C, D, F, G and H
— 200 ×; B — 400 ×, E — 40 ×
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the expression of CCN1 protein is lower in IL-6 defi-
cient mice than in WT animals. The results of immu-
nohistochemical evaluation of CCN1 protein are in
accordance with those obtained by Western blotting.
Although the differences in CCN1 protein quantity
were small and statistically insignificant, differences
in protein distribution between the investigated
groups of mice were more pronounced. In all groups
of animals the strongest immunohistochemical reac-
tion for CCN1 was observed in distal convoluted tu-
bules and in smaller arteries. The main difference in
CCN1 distribution between the mice of the two ex-
amined genotypes was very week reaction in internal
renal medulla and weaker reaction in proximal con-
voluted tubules in IL-6 deficient mice in comparison
to WT ones. Heart failure, evoked by myocardial in-
farction performed twelve weeks earlier, confirmed
by the echocardiographic evaluation and by the ex-
pression of atrial natriuretic peptide in the myocardi-
um of left ventricle, had only small effect on the ex-
pression of CCN1 protein in WT mice kidneys and
had no effect in IL-6 deficient mice. Angiotensin II
upregulates CCN1 synthesis in the cardiovascular sys-
tem and this effect is blunted by blockade of the AT1
receptors [17, 18], however, up till now it was not
known whether similar regulation occurs in the kid-
ney. In pathological conditions AT1 receptor medi-
ates upregulation of proinflammatory genes, includ-
ing IL-6, adhesion molecules, monocyte chemoattrac-
tant protein-1 [24] and promotes accumulation of the
extracellular matrix [25]. It was suggested that AT1
receptor mediates the AngII-induced activation of
nuclear factor kB in the tubular epithelium [26]. In
the experimental model of chronic heart failure syn-
drome in rats, activation of renal AT1R was shown
to contribute to the development of progressive re-
nal dysfunction [21].
In our study blocking of AT1 receptors with telm-
isartan did not have prominent influence on total
CCN1 protein expression in infarcted WT mice,
however, telmisartan treatment attenuated CCN1
expression in the proximal convoluted tubules, which
may suggest a role of angiotensin II in the expression
of CCN1 in this portion of the nephron.
There is only one study which demonstrated CCN1
expression in Balb/c mice normal kidney by the West-
ern blotting method [14]. Unfortunately, authors of
that study did not examine CCN1 protein distribu-
tion in mouse kidney, however, they evaluated the
appearance of CCN1 protein both in mouse and rat
kidney following 40 minutes of bilateral renal is-
chemia. CCN1 protein was detectable in the kidneys
of normal and sham-operated Balb/c mice, and its
levels increased at one hour after ischemia, peaked
at four to eight hours, and CCN1 was still expressed
at 24 hours after ischemia. Although the authors did
not detect CCN1 protein expression in the kidney
from rats subjected to sham surgery, they observed
a dramatic upregulation of CCN1 protein following
40 minutes of bilateral renal ischemia. They also did
not detect any CCN1 mRNA in the kidney of normal
or sham-operated rats using in situ hybridization, how-
ever, two hours after ischemia they observed appear-
ance of the signal in the outer stripe of the outer
medulla and medullar rays, kidney regions which
showed maximal tubular injury following renal is-
chemia/reperfusion. In that study CCN1 mRNA was
primarily expressed in the cytoplasm of proximal
straight tubules that showed mild injury, and was not
detected in the inner medulla of normal or ischemic
rat kidneys. Moreover, CCN1 protein was detected
in urine three to six hours after renal ischemia, and
its concentration peaked at six to nine hours, and
decreased thereafter. Although the role of urinary
CCN1 is unknown, the authors speculate that it might
provide an important signal to a downstream neph-
ron segment [6].
A second study, dealing with CCN1 expression in
rat kidney, was performed in an experimental model
of Thy-1 glomerulonephritis [15]. Contrary to the
previous study, CCN1 protein expression, evaluated
by in situ hybridization, was observed in normal rat
kidney in the outer stripe of outer medulla, which
corresponded to the proximal straight tubules. More-
over, intense expression of CCN1 protein was also
observed in some afferent and efferent arterioles,
however, not in larger vessels. At day 5 of experimen-
tal glomerulonephritis mRNA of CCN1 was detect-
ed on outer surfaces of glomerular basement mem-
brane, which appeared to be podocytes. Similarly to
the above studies performed on rats [14, 15], in all
groups of mice evaluated in the present study we ob-
served CCN1-positive staining in proximal straight
tubules, and contrary to studies performed on rats,
we found the strongest reaction in distal convoluted
tubules. Moreover, contrary to rats, in mouse kidney
we did not observe CCN1-positive staining in affer-
ent and efferent arterioles, but in medium size arter-
ies, while similarly as in rats we did not observe any
reaction in large arteries. In addition, we detected
CCN1-positive staining in mouse glomeruli, proba-
bly in podocytes, which supports earlier findings of
Sawai et al. [15, 27] who detected CCN1 expression
in cultured mouse podocytes.
Some differences in the pattern of CCN1 distri-
bution in normal human kidney as compared to ro-
dents were described by Sawai et al. [27]. CCN1 pro-
tein was expressed in podocytes, the thick ascending
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limb of Henle’s loop, distal and proximal tubules, and
collecting ducts in human kidney. Decreased CCN1
expression in human podocytes was observed in dis-
eases affecting glomeruli, while the intensity of CCN1
staining in the tubular system was not altered [27].
CCN1 was reported to inhibit mesangial cell adhe-
sion and migration and to promote podocyte differ-
entiation and suppress podocyte migration in vitro
[27]. Authors proposed that reduced CCN1 may af-
fect glomerular structure and function by promoting
mesangial migration leading to glomerulosclerosis
and allowing for podocyte migration, that would cause
glomerular crescent formation [27]. Biological effects
of CCN1 depend on the specific membrane receptor
and cell type. CCN1 acts on endothelial cells via inte-
grin avb3 to promote adhesion [28]. CCN peptides
are ligands of integrins aIIß3 in platelets and avb3 in
monocytes [29, 30]. CCN1 also interacts with heparin-
sulfate-containing proteoglycans (HSPGs), including
syndecan 4 and perlecan [31, 32]. Integrins and
HSPGs are essential for the adhesive and mitogenic
function of CCN proteins [31, 32], and syndecan 4
and integrin a6b1 are necessary for CCN1-mediated
induction of apoptosis in fibroblasts [32]. CCN1 is
involved in the inflammatory response by activation
of proinflammatory genetic program in murine mac-
rophages throughout aMb2 and syndecan-4 and is able
to directly induce the expression of certain proinflam-
matory genes, such as TNF-a and IP-10 genes, where-
as upregulation of other proinflammatory genes, in-
cluding IL-1b1 and IL-6, requires the induction of
TNF-a as a mediator [33]. Therefore multiple bio-
logical activities can be elicited through the interac-
tion of discrete domains of the CCN proteins with
different cell membrane receptors.
CCN1 protein expression represents an immedi-
ate early gene response, therefore, regulation of this
protein in the kidney and other organs was mainly
described in experimental models of acute diseases
[14, 15, 17]. Acute kidney ischemia/reperfusion up-
regulates CCN1 expression [14], so it may be hypoth-
esized that early after myocardial infarction there is
also transient induction of CCN1, which might have
delayed alterations of kidney structure and function.
In our model of chronic heart failure we observed
only small changes in the CCN1 expression in mouse
kidney, with a tendency for downregulation of CCN1
twelve weeks after myocardial infarction. Unfortu-
nately, in the present study we have not evaluated the
possible dynamics of CCN1 expression in the kidney,
and there were no evident structural changes in kid-
neys under light microscopy to support the abovemen-
tioned hypothesis.
The present study has demonstrated for the first
time the expression and localization of CCN1 pro-
tein both in wild type and IL-6 deficient C57BL/6J
mouse kidney, both under basic conditions and in
experimental chronic heart failure evoked by myo-
cardial infarction performed twelve weeks earlier. We
have shown that the distribution of CCN1 protein in
mouse kidney presents a pattern different from that
seen in rats, bearing more resemblance to the one
seen in humans. In contrast to rats, in all groups of
mice of both genotypes, the strongest immunohis-
tochemical CCN1-positive reaction was shown in dis-
tal convoluted tubules, and in smaller arteries, while
similarly to rats, CCN1 protein was also present in
proximal straight tubules [14, 15, 27]. In IL-6 defi-
cient mice CCN1 expression, estimated by Western
blot technique, was in the kidney insignificantly low-
er in comparison to WT animals. Experimental heart
failure in mouse kidney caused only slight alterations
of CCN1 protein expression. These alterations affect-
ed mainly proximal convoluted tubules and the inner
part of kidney medulla.
Diminished CCN1 expression may be of impor-
tance in view of the increased fibrosis of the renal
interstitium after myocardial infarction [3]. CCN1
controls fibrosis by inducing senescence of myofibro-
blasts [13], and decreased CCN1 expression may pro-
mote renal fibrosis after infarction. Certainly, CCN1
is not the only one nor the most important regulator
of fibrosis since the most important one seems to be
AngII, as its blockade prevents development of renal
fibrosis [25]. Our results suggest that AngII may con-
siderably downregulate CCN1 in the kidney proximal
tubules.
In summary, we have shown that the expression
of CCN1 protein in IL-6 deficient mouse kidney was
slightly lower in comparison to WT animals, and that
heart failure following myocardial infarction induced
only small alterations of CCN1 protein expression in
mouse kidney.
Acknowledgements
This study was supported by grants N401 103 31/2289
of the Polish Ministry of Science and Higher Educa-
tion and funds from the National Science Center
DEC-2011/01/B/NZ4/04862. Karol Kamiński was sup-
ported by grant from the Foundation for Polish Sci-
ence 05/11.
91CCN1 expression in mouse kidney
©Polish Society for Histochemistry and Cytochemistry




1. Ronco C, Haapio M, House AA, Anavekar N, Bellomo R.
Cardiorenal syndrome. J Am Coll Cardiol. 2008;52:1527–1539.
2. Hillege HL, van Gilst WH, van Veldhuisen DJ et al. Accele-
rated decline and prognostic impact of renal function after
myocardial infarction and the benefits of ACE inhibition: the
CATS randomized trial. Eur Heart J. 2003;24:412–420.
3. Lekawanvijit S, Kompa AR, Zhang Y et al. Myocardial
infarction impairs renal function, induces renal interstitial fi-
brosis, and increases renal KIM-1 expression: implications
for cardiorenal syndrome. Am J Physiol Heart Circ Physiol.
2012;302:H1884–1893.
4. Kaminski KA, Kozuch M, Bonda T et al. Coronary sinus con-
centrations of interleukin 6 and its soluble receptors are af-
fected by reperfusion and may portend complications in pa-
tients with myocardial infarction. Atherosclerosis. 2009;206:
581–587.
5. Hsiao PG, Hsieh CA, Yeh CF et al. Early prediction of acute
kidney injury in patients with acute myocardial injury. J Crit
Care. 2012;27:525 e521–527.
6. Torre-Amione G, Kapadia S, Benedict C et al. Proinflam-
matory cytokine levels in patients with depressed left ventric-
ular ejection fraction: a report from the Studies of Left Ven-
tricular Dysfunction (SOLVD). J Am Coll Cardiol.
1996;27:1201–1206.
7. Bozkurt B, Mann DL, Deswal A. Biomarkers of inflamma-
tion in heart failure. Heart Fail Rev. 2010;15:331–341.
8. Pecoits-Filho R, Lindholm B, Axelsson J, Stenvinkel P.
Update on interleukin-6 and its role in chronic renal failure.
Nephrol Dial Transplant. 2003;18:1042–1045.
9. Naito K, Anzai T, Yoshikawa T et al. Impact of chronic kid-
ney disease on postinfarction inflammation, oxidative stress,
and left ventricular remodeling. J Card Fail. 2008;14:831–838.
10. Kishimoto T, Akira S, Narazaki M, Taga T. Interleukin-6
family of cytokines and gp130. Blood. 1995;86:1243–1254.
11. Klein R, Stiller S, Gashaw I. Epidermal growth factor upreg-
ulates endometrial CYR61 expression via activation of the
JAK2/STAT3 pathway. Reprod Fertil Dev. 2012;24:482–489.
12. Perbal B. CCN proteins: multifunctional signalling regula-
tors. Lancet. 2004;363:62–64.
13. Lau LF. CCN1/CYR61: the very model of a modern matri-
cellular protein. Cell Mol Life Sci. 2011;68:3149–3163.
14. Muramatsu Y, Tsujie M, Kohda Y et al. Early detection of cys-
teine rich protein 61 (CYR61, CCN1) in urine following renal
ischemic reperfusion injury. Kidney Int. 2002;62:1601–1610.
15. Sawai K, Mori K, Mukoyama M et al. Angiogenic protein
Cyr61 is expressed by podocytes in anti-Thy-1 glomerulone-
phritis. J Am Soc Nephrol. 2003;14:1154–1163.
16. Chen Y,Du XY. Functional properties and intracellular
signaling of CCN1/Cyr61. J Cell Biochem. 2007;100:1337–
–1345.
17. Hilfiker-Kleiner D, Kaminski K, Kaminska A et al. Regula-
tion of proangiogenic factor CCN1 in cardiac muscle: impact
of ischemia, pressure overload, and neurohumoral activation.
Circulation. 2004;109:2227–2233.
18. Hilfiker A, Hilfiker-Kleiner D, Fuchs M et al. Expression of
CYR61, an angiogenic immediate early gene, in arterioscle-
rosis and its regulation by angiotensin II. Circulation.
2002;106:254–260.
19. Bouby N, Hus-Citharel A, Marchetti J et al. Expression of
type 1 angiotensin II receptor subtypes and angiotensin II-
-induced calcium mobilization along the rat nephron. J Am
Soc Nephrol. 1997;8:1658–1667.
20. Chansel D, Czekalski S, Pham P, Ardaillou R. Characteriza-
tion of angiotensin II receptor subtypes in human glomeruli
and mesangial cells. Am J Physiol. 1992;262:F432–441.
21. Homma T, Sonoda H, Manabe K et al. Activation of renal
angiotensin type 1 receptor contributes to the pathogenesis
of progressive renal injury in a rat model of chronic cardiore-
nal syndrome. Am J Physiol Renal Physiol. 2012;302:F750–761.
22. Lutgens E, Daemen MJ, de Muinck ED et al. Chronic myo-
cardial infarction in the mouse: cardiac structural and func-
tional changes. Cardiovasc Res. 1999;41:586–593.
23. Kaminski KA, Kozuch M, Bonda TA et al. Effect of interleu-
kin 6 deficiency on the expression of Bcl-2 and Bax in the
murine heart. Pharmacol Rep. 2009;61:504–513.
24. Ruiz-Ortega M, Lorenzo O, Suzuki Y, Ruperez M,Egido J.
Proinflammatory actions of angiotensins. Curr Opin Nephrol
Hypertens. 2001;10:321–329.
25. Ruiz-Ortega M, Ruperez M, Esteban V et al. Angiotensin II:
a key factor in the inflammatory and fibrotic response in kid-
ney diseases. Nephrol Dial Transplant. 2006;21:16–20.
26. Ruiz-Ortega M, Lorenzo O, Ruperez M, Blanco J,Egido J.
Systemic infusion of angiotensin II into normal rats activates
nuclear factor-kappaB and AP-1 in the kidney: role of AT(1)
and AT(2) receptors. Am J Pathol. 2001;158:1743–1756.
27. Sawai K, Mukoyama M, Mori K et al. Expression of CCN1
(CYR61) in developing, normal, and diseased human kid-
ney. Am J Physiol Renal Physiol. 2007;293:F1363–1372.
28. Kireeva ML, Lam SC, Lau LF. Adhesion of human umbilical
vein endothelial cells to the immediate-early gene product
Cyr61 is mediated through integrin alphavbeta3. J Biol Chem.
1998;273:3090–3096.
29. Jedsadayanmata A, Chen CC, Kireeva ML, Lau LF, Lam SC.
Activation-dependent adhesion of human platelets to Cyr61
and Fisp12/mouse connective tissue growth factor is mediat-
ed through integrin alpha(IIb)beta(3). J Biol Chem.
1999;274:24321–24327.
30. Schober JM, Lau LF, Ugarova TP, Lam SC. Identification of
a novel integrin alphaMbeta2 binding site in CCN1 (CYR61),
a matricellular protein expressed in healing wounds and ath-
erosclerotic lesions. J Biol Chem. 2003;278:25808–25815.
31. Chen Y, Abraham DJ, Shi-Wen X et al. CCN2 (connective
tissue growth factor) promotes fibroblast adhesion to fibronec-
tin. Mol Biol Cell. 2004;15:5635–5646.
32. Todorovicc V, Chen CC, Hay N, Lau LF. The matrix protein
CCN1 (CYR61) induces apoptosis in fibroblasts. J Cell Biol.
2005;171:559–568.
33. Bai T, Chen CC, Lau LF. Matricellular protein CCN1 acti-
vates a proinflammatory genetic program in murine macroph-
ages. J Immunol. 2010;184:3223–3232.
Submitted: 20 August, 2012
Accepted after reviews:12 March, 2013
